New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
05:36 EDTAMPEAmpio incorporates Luoxis Diagnostics, COO Josh Disbrow to be CEO if Luoxis
Ampio Pharmaceuticals announced the incorporation and initiation of operations of Luoxis Diagnostics, a subsidiary of Ampio that will initially be funded through a private placement, with Ampio maintaining approximately 80% ownership post financing. Josh Disbrow, Ampio's COO, will assume the role of CEO of Luoxis. Details about the private placement will follow in the near future.
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 22, 2015
08:31 EDTAMPEAmpio announces additional study ersults for Optina
Ampio announced that further data analysis from the 12-week multi-center, placebo-controlled, double-masked randomized trial identified a reversal of pathological changes and a synergistic effect with other medication. As previously reported, oral treatment with Optina has been shown to be safe and confer significant improvements in visual acuity (VA) and reductions in central retinal thickness in patients with diabetic macular edema when given the optimal dose. An independent specialized ophthalmology company reviewed a representative set of images of the eye from the trial and identified positive changes in Optina treated patients compared to placebo. These changes included the reversal of complications such as cystic lesions and subretinal fluid. Additionally, analysis revealed that 69% of the patients in the Optina™ Study received a standard of care medication that manages kidney-induced high blood pressure. The drugs referred to as ACE Inhibitors or ARBs are commonly prescribed to diabetic patients. When this group received the optimal Optina™ dose, they showed a six-letter improvement compared to placebo, regardless of whether or not they previously had anti-VEGF eye injections. There was a significant 34 micron reduction in central retinal thickness over placebo. 60% of these eyes showed a restoration of at least one line of vision compared to only 27% of placebo.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use